AstraZeneca’s Lynparza (olaparib) Receives Fourth FDA’s Orphan Drug Designation to Treat Pancreatic Cancer

 AstraZeneca’s Lynparza (olaparib) Receives Fourth FDA’s Orphan Drug Designation to Treat Pancreatic Cancer

Shots:

  • The Fourth ODD is based on the ongoing P-III POLO study assessing Lynparza (300mg bid) as monotherapy vs PBO in ratio (3:2) & 1EP as PFS in 145 patients with BRCA-mutated mPC
  • Results of POLO P-III study is expected in H1’19
  • In Oct 2013, Lynparza received ODD for the treatment of ovarian cancer and in Aug 2017, ODD was to treat recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer with expanded label including fallopian tube and primary peritoneal cancers in H1’18

Click here to read full press release/ article | Ref: AstraZeneca | Image: ET HealthWorld

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post